Ossio
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind. Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents a breakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind. Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now.
Ossio has raised $66.1M across 2 rounds. Its most recent round was a Series Unknown of $27.6M in Dec 2024. Full funding history, investors, and team are detailed below.
Funding history
2 rounds on record — latest round shown, the rest unlock with a paid plan.
Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Ossio is featured in
Similar companies
Intellihealth creates medical technology software that aids in diagnosing diseases associated with obesity. One of the company's primary offerings, Evolve, allows healthcare professionals to provide effective obesity treatment to patients, whether through telehealth or in-person consultations.
Ember Copilot is a Software Development firm offering a tool to reduces medical claim denials.
Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology care delivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home. It was founded in 2020 and is based in Nashville, Tennessee.
QSimulate is currently hiring for various positions such as scientists, software engineers, project managers, and business development, as the team expands. Our office locations include Boston MA, Berkeley CA, and Ghent, Belgium. Remote options are also considered for technical roles. For further details, please contact us at info@qsimulate.com.
100 Healthy Years • Your new routine of 120+ advanced lab tests explained by the world's top doctors
Perelel is a supplement manufacturer designed for various stages of a woman's reproductive life cycle.
House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.
DifferentKind is a software solution designed for dental professionals to focus on patient needs, allowing them to enhance patient results and satisfaction. This ultimately leads to increased trust, loyalty, and revenue for dental practices. The software utilizes AI technology for clinical consultations and executive decision-making.
NextSense opens mind wellbeing with genuine information experiences and useful, logical insight for everyday living. It plans to catalyze cerebrum wellbeing in science and culture. The organization was established in 2020 and is settled in Mountain View, California.
MR3Health is a unique new organization that brings an inventive mix of administration and demonstrated innovation to patients and guarantors to save lives impacted by diabetic neuropathy and lower the expenses of medical services. MR3Health is extraordinarily situated for progress with various assets obscure to most new businesses. These incorporate existing licenses, a FDA cleared clinical gadget upheld by clinical preliminaries, and a supervisory crew with an abundance of business, assembling, and clinical experience. It was sent off in 2015 and is settled in San Antonio, Texas.
MiSalud offers a unique combination of personalized preventative wellness services, along with traditional healthcare via Spanish speaking physicians.
Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.